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Abstract 
Background: While the process of sepsis‑induced immunosuppression is now well described in adults, very lit‑
tle information is available on immune functions in pediatric sepsis. The current study investigated this in children 
with septic shock by performing immunomonitoring, including both innate (monocyte human leukocyte antigen‑
DR, mHLA‑DR, expression) and adaptive immunity (lymphocyte subsets count), as well as cytokine concentrations 
(IL‑6, IL‑8, IL‑10, IL‑1Ra, TNF‑α, IFN‑γ). Subsequent objectives were to assess the associations between inflammatory 
response, potential immunosuppression and secondary acquired infection occurrence.
Methods: Single‑center prospective observational study, including children aged between 1 month and 18 years 
admitted to pediatric intensive care unit (PICU) for septic shock. Age‑matched controls were children hospitalized 
for elective surgery without any infectious criteria. Blood was sampled at day 1–2, 3–5, and 7–9 after sepsis onset. 
mHLA‑DR and lymphocyte subsets count were measured by flow cytometry and cytokine concentrations by Luminex 
technology.
Results: A total of 26 children and 30 controls were included. Patients had lymphopenia, and mHLA‑DR levels were 
significantly lower than controls at each time point (p < 0.0001). All cytokines peaked at day 1–2. Children with sec‑
ondary acquired infection had lower day 3–5 mHLA‑DR and higher pro‑inflammatory cytokine concentrations (IL‑6, 
IL‑8 and TNF‑α) at day 1–2 compared to children without secondary acquired infection.
Conclusions: The higher initial inflammatory cytokine production was, the more innate immunity was altered, while 
evaluated by low mHLA‑DR expression. Children with decreased mHLA‑DR expression developed more secondary 
acquired infections. Upon confirmation in multicenter cohorts, these results pave the way for immunostimulation for 
the most immunosuppressed children in order to prevent nosocomial infections in PICU.
Trial registration PedIRIS study NCT02848144. Retrospectively registered 28 July 2016
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Background
Despite advances in critical care management, septic 
shock remains one of the most important causes of mor-
tality and morbidity in children worldwide [1]. As for 
adults, the inability of adjunctive therapies to mitigate 
the deleterious effects of this condition indicates that it 
is likely that initial hypotheses for sepsis pathophysiol-
ogy have been inadequately addressed [2]. In adults, it is 
now agreed that sepsis deeply perturbs immune balance 
by inducing a strong systemic inflammatory response 
and a concomitant anti-inflammatory process, acting as a 
negative feedback. This compensatory response may sec-
ondarily become harmful as most immune functions are 
compromised, and thus sepsis-induced immune altera-
tions may play a major role in the decreased resistance 
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to secondary acquired infections in patients who initially 
survive [3]. This immunosuppressive state is character-
ized by both abnormal innate and adaptive immune 
responses. In particular, patients mostly present with 
marked lymphopenia and decreased expression in mono-
cyte human leukocyte antigen-DR (mHLA-DR). The 
latter remains, to date, the key parameter of patient mon-
itoring and its diminished expression has been reported 
to be associated with increased mortality and nosocomial 
infection rate in adults [4–6]. In this context, and as it 
is already the case for cancer immunotherapy, targeted 
treatments aimed at rejuvenating immune responses in 
adult septic patients (e.g., GM-CSF, Interleukin-7, anti-
PD-1/-L1) are now envisaged [7–10]. In comparison with 
adults, data are very scarce in children with septic shock. 
The impact of this altered immune response on second-
ary infections is poorly reported in children affected by 
septic shock. In order to envisage therapeutic interven-
tions to restore immune function in children, a reliable 
biomarker is required to identify children at highest risk 
of secondary acquired infection or mortality. Such a 
marker is currently lacking in children. Most pediatric 
results are rarely specific of septic shock. They refer, as 
a whole, to various pediatric intensive care unit (PICU) 
admission causes (surgery, organ dysfunctions) [11–14], 
or are limited to particular cases of preterm neonates 
[15, 16]. Thus, the objective of the present prospective 
observational study was to investigate whether pediatric 
septic shock patients present immune alterations simi-
lar to those seen in adults. For this, immunomonitoring 
was performed during the first week after sepsis onset. 
This monitoring included mHLA-DR, lymphocyte sub-
sets count, and phenotyping as well as measurement of 
plasma cytokine concentrations: interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necro-
sis factor-α (TNF-α), interferon-γ (IFN-γ), and interleu-
kin-1 receptor antagonist (IL-1Ra). As control values may 
depend on age, and in the absence of mHLA-DR refer-
ence range in pediatrics, healthy children were also inves-
tigated to explore mHLA-DR expression during the first 
years of life.
Methods
Study population
This single-center, prospective study was held in PICU 
from a tertiary academic hospital (23 beds mixed med-
ical-surgical unit, > 1100 admissions/year). Children, 
aged from 1 month to 18 years, were included prospec-
tively during 24 h of PICU admission, if they presented 
septic shock, defined by “Surviving Sepsis Campaign” 
and Goldstein’s criteria [17, 18]. Exclusion criteria were: 
non-septic shock, chronic inflammatory disease, long-
term corticosteroid treatment, transplantation and/or 
immunosuppressive therapy, immunodeficiency syn-
drome, malignant tumors. Opposition from the child 
and/or parent/holder of parental authority also consti-
tuted exclusion criteria. Controls were age-matched to 
the case group and identified among outpatients admit-
ted for a scheduled surgery, without any criteria of infec-
tion. Exclusion criteria were the same as the case group. 
Three age subgroups were defined: 1  month to 2, 2–8, 
and > 8  years, according to the physiological age-based 
development of immunity in children [19].
Clinical data and definitions
Clinical data were collected prospectively and obtained 
from the electronic medical record. At admission (day 1), 
severity of illness was evaluated using the pediatric index 
of mortality 2 (PIM2) [20]. Organ failure was assessed 
by the measurement of PEdiatric Logistic Organ Dys-
function Score, version 2 (PELOD-2) at day 1, 3, and 7 
[21]. Vasoactive treatments during hospitalization in 
PICU were determined by the cumulative vasopressor 
index (CVI) [22]. We also collected incidence of second-
ary acquired infection, mortality (death occurring within 
28  days after the onset of shock), number of mechani-
cal ventilation-free days, and number of PICU-free days 
in the first 30  days. Secondary acquired infection was 
defined by Center for Disease Control criteria, included 
any new bacterial or fungal infection, distinct from initial 
infection, occurring more than 48  h after sepsis onset, 
during the first 30 days after sepsis onset [23]. Determi-
nation of secondary acquired infection was performed 
prospectively by one physician (SR), blinded to immuno-
logical data.
Blood sampling for immunomonitoring
Blood samples were collected within the first 48 h after 
the onset of infection, again between day 3–5, and day 
7–9. Samples were not available if patients were no longer 
in PICU. Blood was collected in EDTA tubes, transported 
rapidly at 4  °C to the Cellular Immunology Laboratory, 
and analyzed within less than 4 h. The amount of blood 
sample did not exceed 2.4  ml/kg, in accordance with 
European recommendations. At each time point, the fol-
lowing parameters were determined by flow cytometry: 
mHLA-DR, total lymphocytes and lymphocytes sub-
populations  (CD4+ and  CD8+ T cells, natural killer [NK] 
cells, regulatory T cells [Treg], and B cells). In addition, 
after completion of cellular analysis, plasma was obtained 
after centrifugation and stored at − 80 °C for subsequent 
quantification of following circulating cytokines: IL-6, 
IL-8, IL-10, IL-1RA, TNF-α, and IFN-γ. For the control 
group, blood was sampled in the operating room imme-
diately after induction of general anesthesia with sevoflu-
rane, before start of surgery.
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Flow cytometry
Quantification of mHLA-DR on circulating monocytes 
was performed using a standardized flow cytometric 
assay as previously described [24.] The median fluores-
cence intensity of the entire monocyte population was 
then transformed to number of antibodies bound per cell 
(ABC) using calibrated PE beads (BD QuantiBRITE™ PE 
Beads, Becton–Dickinson San Jose, CA, USA). The fol-
lowing lymphocyte subsets were analyzed by flow cytom-
etry as previously described [25, 26]: total T lymphocytes 
 (CD45+  CD3+),  CD4+ T lymphocytes  (CD45+  CD4+ 
 CD3+),  CD8+ T lymphocytes  (CD45+  CD8+  CD3+), 
total B cells  (CD45+  CD19+), NK cells  (CD45+  CD3− 
 CD56+), and Treg  (CD4+  CD25+  CD127−). Results were 
expressed as numbers of cells per microliter of blood for 
lymphocyte subsets and as percentage of positive cells 
among total  CD4+ lymphocyte population for Treg.
Cytokine measurement
IL-6, IL-8, IL-10, IL-1RA, TNF-α, and IFN-γ were 
quantified with a single panel  (Milliplex® MAP Human 
Cytokine/Chemokine Magnetic Bead Panel, Merck Mil-
lipore) using the fluorescent bead-based multiplexed 
Luminex xMAP technology [27]. Analyses were per-
formed on Bio-Plex 200 Luminex instrument using Bio-
Plex software (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Results are expressed as median and interquartile range 
[IQR]. Comparisons between groups were analyzed using 
the Man–Whitney U test for continuous nonparametric 
variables; the independent paired t test for continuous 
parametric variables and the Chi-square test for categori-
cal data. Correlation analyses were performed using the 
Pearson test for variables following a normal distribution, 
and Spearman for nonparametric variables. Kaplan–
Meier analyses were performed using Youden’s index to 
stratify groups of patients. A p value < 0.05 was consid-
ered to represent significant statistical difference. Data 
were analyzed by using Prism6 software (GraphPad Inc., 
La Jolla, CA, USA).
Results
Subjects
Between September 2014 and July 2016, 73 children 
were screened for septic shock. Among these, 47 were 
excluded (toxic shock syndrome, non-infectious shock, 
known immunosuppression, or chronic inflammatory 
disease). A total of 26 children were included and ana-
lyzed (Fig. 1). Demographic data are presented in Table 1. 
Nine children (35%) presented a complex chronic condi-
tion. The most frequent was prematurity (n = 4), but all 
children presented a corrected age greater than 1 month. 
Others presented psychomotor delay (n = 2), polymal-
formative disease (n = 2), and sickle cell disease (n = 1). 
Two children died: one precociously at day 2, due to 
refractory shock with multi-organ failure; and the sec-
ond one at day 32, with withdrawal treatment for major 
brain damage after meningitis. A total of 30 healthy chil-
dren were included as controls. They were age-matched 
with children in septic shock (p = 0.3, Mann–Whitney): 
11 were aged between 1 month and 2 years, 14 between 2 
and 8 years, and 5 > 8 years.
mHLA‑DR expression
In healthy control children, mHLA-DR was > 25,000 
ABC; among those aged between 1  month to 2  years it 
was (median [IQR]) 25,477 ABC [20,478–39,143], among 
those aged 2–8 years it was 34,295 ABC [25,763–43,368], 
and among those older than 8  years it was 29,597 ABC 
[26,636–41,939]; there was no significant difference 
between age subgroups (p = 0.35; ANOVA, Fig.  2a). 
There was also no correlation between age and mHLA-
DR (r = 0.018).
In children with septic shock, mHLA-DR was 6066 
ABC [3737–16,310] at day 1–2, 6308 ABC [3185–8965] 
at day 3–5, and 9323 ABC [6384–12,738] at 7–9; at each 
time point values were significantly different to that 
found in healthy control children (p < 0.0001; Fig.  2b). 
There was no correlation between mHLA-DR and PIM2 
or PELOD-2 scores, at any time point, while a significant 
correlation was found between day 3–5 mHLA-DR and 
CVI (r = − 0.50; p = 0.031; Fig. 2c).
Assessed for 
eligibility
(n=73)
Included
(n=44)
Analysed
(n=26)
Retrospectively excluded (n=18)
- 10 Toxic Shock Syndrome
- 5 non infectious shock
- 2 unknown immunosuppressed
- 1 unknown chronic inflammatory disease
Excluded (n=29)
- 10 aged < 10 months
- 8 immunosuppressed
- 4 died within 24 hours
- 6 parental refusal
- 1 chronic inflammatory disease
Fig. 1 Flowchart
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Cytokines
For all cytokines, maximal elevated values were meas-
ured on early time point. Then, they presented a gradual 
decrease on following days but remained significantly 
elevated in comparison with normal values (Table  2). 
At day 1–2, IL-6 and IL-8 levels were significantly cor-
related with PELOD-2 (r = 0.52, p = 0.012 and r = 0.43, 
p = 0.048, respectively) and with CVI (r = 0.65, p = 0.001 
and r = 0.51, p = 0.015, respectively). No correlation 
between initial cytokines concentrations and PIM2 score 
was found. Also, there was no correlation between ini-
tial cytokines levels and mHLA-DR at day 1–2. How-
ever, IL-8, IL-10, IL-1ra and TNF-α levels at day 1–2 
were significantly negatively correlated with mHLA-DR 
at day 3–5 (r = − 0.84, p < 0.0001; r = − 0.59, p = 0.0198; 
r = − 0.58, p = 0.023; r = − 0.69, p = 0.0042, respectively).
Lymphocyte subsets
Lymphocyte subsets from healthy control children are 
presented in Table  3. Among septic patients the total 
lymphocyte count was significantly lower than in healthy 
control children at day 1–2 and day 3–5; there was no 
significant difference at day 7–9 (Fig. 3a). Similar results 
were observed for  CD4+ (Fig.  3b) and  CD8+ T cell 
(Fig. 3c) subsets. The median total NK cell count was sig-
nificantly lower as compared to healthy control children 
over the whole monitoring period (Fig.  3d). In contrast 
and, although diminished, B cells were modestly affected 
(Fig.  3e). The median proportion of Treg was initially 
similar to that found in healthy control children; this 
increased at day 3–5, and became significantly greater at 
day 7–9 (Fig. 3f ). Of note, we did not find any correlation 
between lymphocytes subsets and CVI (data not shown).
Secondary acquired infections
A secondary acquired infection was diagnosed in eight 
children (Additional file 1: Tables S1 and S2). The median 
time to onset of these infections was 13.5  days (range: 
[9–25]). Compared to children who did not developed 
secondary acquired infection, the sole difference was a 
longer length of hospital stay for children who presented 
secondary acquired infection (p = 0.009; Additional file 1: 
Table S1). Between these two groups, no difference was 
observed concerning duration of invasive equipment, 
PICU staying, complex chronic condition and sever-
ity scores. No significant difference in lymphocyte sub-
set was observed between children with or without 
secondary acquired infections. No association was found 
between persistent lymphopenia (defined as an absolute 
lymphocyte count of < 1000 cells/µl for 3 days) and devel-
opment of secondary acquired infection. At day 1–2, 
there was no significant difference in mHLA-DR values; 
at day 3–5 those with secondary acquired infection had a 
significantly lower level of mHLA-DR (4398 ABC [2437–
6212]) than those without (8474 ABC [5904–10,844], 
p = 0.022; Fig.  2d). At day 1–2, children with secondary 
acquired infection had higher concentrations of IL-6, 
IL-8, and TNF-ɑ than those without (Additional file  1: 
Table S1). There was no significant difference in cytokine 
concentrations at other time points. The area under the 
curve from receiver operating curve (ROC) analysis for 
the risk to develop a secondary acquired infection were 
all significantly > 0.8 for these four significant parameters 
Table 1 Characteristics of the 26 children with septic 
shock included in the study
Values are expressed as median [interquartile range], or a number (percentage)
PIM2 pediatric index of mortality 2, PELOD-2 PEdiatric Logistic Organ 
Dysfunction score, version 2, CVI cumulative vasopressor index
Septic shock (n = 26)
Age (years) 2.12 [0.47–4.60]
Male gender [n (%)] 11 (42)
Complex chronic conditions [n (%)] 9 (35)
Primary nosocomial infection 1 (3.9)
Site of initial infection [n (%)]
 Blood 3 (11.5)
 Lung 4 (15.4)
 Abdomen 8 (30.8)
 Multi‑site 9 (34.6)
 Others 1 (3.9)
 No documentation 1 (3.9)
Microbiology
 Gram‑negative bacteria
  Neisseria meningitidis 8 (30.8)
  Escherichia coli 3 (11.5)
  Klebsiella species 2 (7.7)
  Enterobacter species 2 (7.7)
  Campylobacter jejuni 1 (3.8)
  Haemophilus influenzae 1 (3.8)
 Gram‑positive bacteria
  Streptococcus pneumoniae 3 (11.5)
  Streptococcus pyogenes 2 (7.7)
  Staphylococcus aureus 1 (3.8)
 Viruses
  Parainfluenzae virus 1 (3.8)
PIM2 admission (%) 8.1 [3.2–17.4]
PELOD‑2
 Day 1 9.5 [2.75–12.0]
 Day 3 4.0 [0.0–10.0]
 Day 7 0.0 [0.0–5.0]
CVI 4.0 [0.0–7.0]
ICU‑free days in 30 days 23.0 [19.0–26.0]
Secondary acquired infections [n (%)] 8 (30)
Mortality [n (%)] 2 (7)
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(mHLA-DR at day 3–5, and IL-6, IL-8 and TNF-ɑ at day 
1–2, Additional file 1: Table S3). In line with this, mHLA-
DR at day 3–5 was negatively correlated with cytokines 
(except IFN-γ). Owing to the sample size, no multivari-
ate regression could be performed to test independence 
between mHLA-DR and cytokines for the prediction of 
risk of secondary acquired infection occurrence.
We next performed Kaplan–Meier analyses associ-
ating mHLA-DR values and each cytokine level sepa-
rately, which found that children with lowest values of 
mHLA-DR and highest cytokine levels were significantly 
more likely to be infected. Those with mHLA-DR above 
the threshold remained uninfected, independently of 
cytokine level (Additional file 1: Fig. S1).
< 2 years 
N=11
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N=14
> 8 years 
N=5
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Fig. 2 mHLA‑DR measurements in pediatric septic shock. a mHLA‑DR expression in healthy children: no difference according to age groups 
(p = 0.35; ANOVA). Dashed line depicts usual threshold to define normal values in adults. b mHLA‑DR was significantly decreased at each time point 
during septic shock, than controls (p < 0.001; Mann–Whitney). c mHLA‑DR at day 3–5 was significantly negatively correlated with cumulative vaso‑
pressor index, CVI (r = − 0.50; p = 0.031; Spearman). d mHLA‑DR was significantly lower in children with secondary acquired infection than those 
without (p = 0.022; Student t test)
Table 2 Plasma cytokines levels from healthy children and children with septic shock
Values (pg/ml) are expressed as median [IQR]. All cytokine values in children with septic shock at all-time points were different from those of healthy controls
Healthy controls Children with septic shock
Day 1–2 Day 3–5 Day 7–9
IL‑6 0.0 [0.0–0.36] 178.5 [25.77–3311] 18.13 [12.92–172.5] 17.97 [3.30–33.08]
IL‑8 2.05 [0.43–5.06] 51.72 [19.07–145.7] 21.45 [11.42–56.36] 15.00 [7.98–37.98]
IL‑10 0.36 [0.0–4.44] 43.37 [17.11–331.6] 8.26 [3.44–21.66] 11.83 [1.70–23.73]
IL1‑RA 0.0 [0.0–17.16] 136.9 [23.72–647.8] 48.02 [0.0–153.2] 56.54 [0.0–121.3]
TNF‑α 4.91 [3.35–7.11] 25.13 [14.52–40.47] 8.37 [5.34–14.62] 10.15 [4.10–15.43]
INF‑γ 4.98 [1.82–6.45] 15.81 [6.55–24.22] 8.07 [2.78–11.45] 10.92 [4.65–23.70]
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Discussion
The present investigation is, to the best of our knowledge, 
the first prospective pediatric study reporting a wide 
immune monitoring, specifically in septic shock. How-
ever, the first important result of this study is the values 
of mHLA-DR expression in healthy children. There was 
no variation according to age (between 6  months and 
17 years) and, furthermore, the values are not different to 
those reported in adults [28]. These results strongly sug-
gest that there is no difference between healthy adults 
and children in terms of mHLA-DR expression. Impor-
tant fall in mHLA-DR during pediatric septic shock 
seems to be similar to those observed during adult septic 
shock.
The cytokine storm reported herein, involving both pro 
and anti-inflammatory cytokines, was found in the initial 
period after shock (day 1–2). At the same time, children 
who later developed a secondary acquired infection had 
higher plasma cytokine concentrations (i.e., IL-6, IL-8, 
and TNF-α). This is in agreement with observations 
from genomic studies that have found that early mRNA 
expression modulations of cytokines and apoptotic genes 
were associated with deleterious outcomes (mortal-
ity, secondary infections) [29, 30]. Moreover, to the best 
of our knowledge, this is the first pediatric study which 
reported correlation between initial cytokine storm and 
alteration of innate immunity, represented by loss of 
mHLA-DR.
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Concerning adaptive immunity, B and T lymphocytes 
were diminished initially, but less impacted and corrected 
faster than mHLA-DR alteration. The modest diminu-
tion of B cells constitutes a difference with that found 
in adults, for instance Monserrat et  al. [31] described 
severe abnormality of circulating B lymphocytes associ-
ated with mortality. Concerning NK cells, Halstead et al. 
[32] observed a decrease at the beginning of sepsis in 
children. The present study provides supplementary data 
since a deep and prolonged alteration of circulating NK 
cells was found. Although we did not explore this side, 
NK cell alterations could promote infections by oppor-
tunistic viral pathogens [33]. In contrast with the study 
reported by Muszynski et  al. [14], an increase in Treg 
proportion during the first week was observed herein. 
This kinetic seems similar to that described in adult sep-
tic shock, where an increased proportion of Treg was 
associated with poor outcome [34]. Here, as for other 
lymphocyte parameters, no association with nosocomial 
infections was found. Additional functional testing (pro-
liferation, intracellular cytokine production) would be 
likely informative and deserves to be further investigated. 
At this stage, the present lymphocyte data seem to indi-
cate that altered lymphocyte count rapidly self-resolves, 
in contrast with observations made in adults.
With regards to innate immunity, loss of mHLA-
DR has emerged as a gold standard biomarker owing 
to its association with altered monocyte functionality, 
increased mortality, and nosocomial infection rate after 
adult septic shock [6, 35]. In accordance, we report here 
a significant fall in mHLA-DR in children. Importantly, 
the lowest values at day 3–5 were found in patients who 
developed secondary acquired infections. At this time 
point, all patients with forthcoming infections presented 
mHLA-DR below 8000 ABC (i.e., the usual threshold 
for defining the most severely immunosuppressed adult 
patients [36]). Most pediatric studies have used ex  vivo 
LPS-induced TNF-α production by monocytes to assess 
innate immunity function. However, Drewry et  al. [35] 
presented recently mHLA-DR as a better predictor of 
deleterious outcomes than LPS-stimulated TNF-α pro-
duction. Add to our results, these data reinforced the 
idea to use mHLA-DR as biomarker of altered innate 
immunity in pediatric studies. Due to low number of 
deaths in the present cohort, we did not investigate the 
potential association with mortality. Although not all 
obtained using a standardized measurement protocol, 
the pediatric mHLA-DR data available in the literature 
are in agreement with that reported herein. For exam-
ple, Manzoli et  al. [13] found the extent of mHLA-DR 
level reduction during the first week after sepsis onset to 
be associated with mortality (23% mortality), and Genel 
et al. [16] also reported lower levels of mHLA-DR among 
infected neonates who did not survive compared to those 
who did (20% mortality). Decreased mHLA-DR has also 
been described in pediatric surgery and was associated 
with later sepsis and pneumonia [37, 38]. In addition, 
Hall et  al. [11] reported that, in children with multi-
ple organ dysfunction syndrome, persistent decreased 
TNF-α release (that reflects monocyte functionality) over 
5  days was associated with development of secondary 
infection. In addition, some in  vitro and animal studies 
suggest potential role of norepinephrine in the develop-
ment of sepsis-induced immunosuppression [39]. These 
data reinforced our significant correlation between day 
3-5 mHLA-DR and CVI.
Collectively, this indicates that, as in adults, mHLA-
DR presents potential for the identification of the most 
severe immunosuppressed children. The next step 
would, of course, be to perform multivariate analysis in 
a larger patient sample to explore the independence of 
each parameter in predicting deleterious outcomes. That 
given, Kaplan–Meier analyses found that although differ-
ent markers (i.e., day 3–5 mHLA-DR and early elevated 
cytokines) were associated with secondary acquired 
infections, the weight of mHLA-DR was more important. 
Interestingly, as observed in adult trauma patients, asso-
ciation between early cytokines production and low day 
3–5 mHLA-DR appeared as the poorest scenario in pedi-
atric septic shock [40].
Furthermore, secondary acquired infections repre-
sent a major economic burden by significantly extending 
length of hospital stay [41, 42], and concordantly herein 
the length of hospitalization in those with secondary 
infection doubled (and this difference was significant). 
Taken together, these data reinforce the idea that most 
immunosuppressed septic children might benefit from 
immunostimulation as an adjunctive therapy [43]. Clini-
cal trials are in progress with GM-CSF (NCT02361528) 
or IL-7 (NCT02640807/NCT02797431) in adults, and 
standardized tools are currently used to stratify patients 
in those trials. This progressively paves the way for this 
kind of approach in pediatrics, especially for innate 
immunity that seems to be more affected.
The study does, however, have some limitations. First, 
the relatively small number of included children pre-
cluded multivariate analyses to be performed. Second, 
some children were discharged from PICU before all 
samples were obtained, and therefore the time course of 
different immune parameters in less severe children was 
not determined. Due to the relatively short follow-up 
period, we cannot conclude on the long-term outcome of 
these children treated for septic shock. In addition, func-
tional testing should be performed in next studies. The-
ses aspects need to be further explored, and ideally in a 
multicenter study.
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Conclusion
As in adults, septic shock in pediatric patients induced 
marked alterations in immune parameters in accordance 
with the occurrence of a state of immunosuppression. 
The present results, in particular the association between 
low mHLA-DR expression and deleterious outcomes, 
deserves to be assessed and confirmed in multicenter 
studies.
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